Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug class
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
fusion inhibitors
CCR5 antagonists post-attachment inhibitors |
| gptkbp:combines |
other antiretroviral drugs
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:example |
gptkb:enfuvirtide
ibalizumab maraviroc |
| https://www.w3.org/2000/01/rdf-schema#label |
HIV entry inhibitors
|
| gptkbp:mechanismOfAction |
block HIV entry into host cells
|
| gptkbp:notEffectiveAgainst |
HIV strains using CXCR4 coreceptor
|
| gptkbp:notFirstLineTherapy |
true
|
| gptkbp:resistantTo |
coreceptor switching
mutations in HIV envelope proteins |
| gptkbp:routeOfAdministration |
injection
oral |
| gptkbp:sideEffect |
injection site reaction
hepatotoxicity hypersensitivity |
| gptkbp:subclassOf |
antiretroviral drugs
|
| gptkbp:target |
HIV envelope proteins
host cell receptors |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:gp41
|
| gptkbp:bfsLayer |
6
|